1. Home
  2. PROK vs FRGE Comparison

PROK vs FRGE Comparison

Compare PROK & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROK
  • FRGE
  • Stock Information
  • Founded
  • PROK 2015
  • FRGE 2014
  • Country
  • PROK United States
  • FRGE United States
  • Employees
  • PROK N/A
  • FRGE N/A
  • Industry
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • FRGE Computer Software: Prepackaged Software
  • Sector
  • PROK Health Care
  • FRGE Technology
  • Exchange
  • PROK Nasdaq
  • FRGE Nasdaq
  • Market Cap
  • PROK 85.5M
  • FRGE 175.1M
  • IPO Year
  • PROK N/A
  • FRGE N/A
  • Fundamental
  • Price
  • PROK $0.58
  • FRGE $18.93
  • Analyst Decision
  • PROK Hold
  • FRGE Buy
  • Analyst Count
  • PROK 3
  • FRGE 5
  • Target Price
  • PROK $3.50
  • FRGE $38.25
  • AVG Volume (30 Days)
  • PROK 1.6M
  • FRGE 122.0K
  • Earning Date
  • PROK 08-08-2025
  • FRGE 08-06-2025
  • Dividend Yield
  • PROK N/A
  • FRGE N/A
  • EPS Growth
  • PROK N/A
  • FRGE N/A
  • EPS
  • PROK N/A
  • FRGE N/A
  • Revenue
  • PROK $306,000.00
  • FRGE $85,383,000.00
  • Revenue This Year
  • PROK $54.34
  • FRGE $18.22
  • Revenue Next Year
  • PROK N/A
  • FRGE $29.35
  • P/E Ratio
  • PROK N/A
  • FRGE N/A
  • Revenue Growth
  • PROK N/A
  • FRGE 16.04
  • 52 Week Low
  • PROK $0.46
  • FRGE $6.60
  • 52 Week High
  • PROK $2.59
  • FRGE $24.45
  • Technical
  • Relative Strength Index (RSI)
  • PROK 39.26
  • FRGE 73.21
  • Support Level
  • PROK $0.54
  • FRGE $18.15
  • Resistance Level
  • PROK $0.90
  • FRGE $19.94
  • Average True Range (ATR)
  • PROK 0.13
  • FRGE 0.97
  • MACD
  • PROK -0.02
  • FRGE 0.19
  • Stochastic Oscillator
  • PROK 9.55
  • FRGE 84.67

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

About FRGE Forge Global Holdings Inc.

Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.

Share on Social Networks: